Puzzling results from HIV vaccine trial

Dec 03, 2007

A potential HIV vaccine that recently failed a clinical trial in the United States may increase some people's chance of catching the virus that causes AIDS.

Top government and drug industry scientists are currently reviewing data from the trial, which unexpectedly found more HIV infections among study participants who had previously been exposed to a common virus called adenovirus, The Washington Times reported Monday.

"We're trying very hard to understand the data more fully and completely," says Nalini Saligram, a spokeswoman for Merck, co-sponsor of the STEP vaccine trial.

Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Disease, called the trial results "both disappointing and puzzling."

The trial involved 3,000 participants between the ages of 18 and 45 who were at risk of HIV infection based on their behavior.

It ended in September after researchers determined the vaccine failed to decrease either the chance of HIV infection or the amount of virus in people who became infected while taking it.

Copyright 2007 by United Press International

Explore further: US judge orders HIV-positive man to stop infecting others

add to favorites email to friend print save as pdf

Related Stories

Human clinical trial of DNA-MVA HIV vaccine candidate begins

Sep 28, 2010

A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost vaccine regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa ...

Spanish doctors unveil promising AIDS vaccine

Feb 01, 2011

Spanish researchers announced Tuesday they have developed an AIDS vaccine which cuts the viral load by a significant amount in most patients although they cautioned it is still not enough as a treatment.

Consortium to design human trials of mosaic HIV vaccine

Oct 18, 2010

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel ...

Recommended for you

The genetics of coping with HIV

21 hours ago

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

Puerto Rico partners on US HIV vaccine project

Sep 10, 2014

Puerto Rico's governor says the island's largest public university is partnering with federal agencies to oversee a U.S.-funded project aimed at trying to develop a prophylactic vaccine for the HIV virus that causes AIDS.

User comments : 0